Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
29 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hypothyroidism - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypothyroidism - Pipeline Review, H2 2016, provides an overview of the Hypothyroidism (Hormonal Disorders) pipeline landscape. Hypothyroidism (underactive thyroid) is a condition in which thyroid gland doesn't produce enough of certain important hormones. Signs and symptom include fatigue, constipation, dry skin, puffy face, muscle weakness, muscle aches, tenderness and stiffness, pain and stiffness. Risk factors include autoimmune diseases, thyroid surgery, radiation therapy and family history of thyroid disease. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypothyroidism - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hypothyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hypothyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypothyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III and Preclinical stages are 1 and 5 respectively.Hypothyroidism. Hypothyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hypothyroidism (Hormonal Disorders). - The pipeline guide reviews pipeline therapeutics for Hypothyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hypothyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hypothyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hypothyroidism (Hormonal Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hypothyroidism (Hormonal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hypothyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Hypothyroidism Overview 6 Therapeutics Development 7 Pipeline Products for Hypothyroidism - Overview 7 Hypothyroidism - Therapeutics under Development by Companies 8 Hypothyroidism - Pipeline Products Glance 9 Late Stage Products 9 Early Stage Products 10 Hypothyroidism - Products under Development by Companies 11 Hypothyroidism - Companies Involved in Therapeutics Development 12 Synthonics Inc 12 Titan Pharmaceuticals Inc 13 Hypothyroidism - Therapeutics Assessment 14 Assessment by Monotherapy Products 14 Assessment by Combination Products 15 Assessment by Target 16 Assessment by Mechanism of Action 17 Assessment by Route of Administration 18 Assessment by Molecule Type 20 Drug Profiles 21 (levothyroxine + liothyronine) - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 BCT-305 - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 levothyroxine sodium SR - Drug Profile 23 Product Description 23 Mechanism Of Action 23 R&D Progress 23 liothyronine - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 liothyronine sodium - Drug Profile 25 Product Description 25 Mechanism Of Action 25 R&D Progress 25 liothyronine sodium SR - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 Hypothyroidism - Dormant Projects 27 Appendix 28 Methodology 28 Coverage 28 Secondary Research 28 Primary Research 28 Expert Panel Validation 28 Contact Us 28 Disclaimer 29
List of Tables
Number of Products under Development for Hypothyroidism, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Late Stage Development, H2 2016 9 Comparative Analysis by Early Stage Development, H2 2016 10 Products under Development by Companies, H2 2016 11 Hypothyroidism - Pipeline by Synthonics Inc, H2 2016 12 Hypothyroidism - Pipeline by Titan Pharmaceuticals Inc, H2 2016 13 Assessment by Monotherapy Products, H2 2016 14 Assessment by Combination Products, H2 2016 15 Number of Products by Stage and Target, H2 2016 16 Number of Products by Stage and Mechanism of Action, H2 2016 17 Number of Products by Stage and Route of Administration, H2 2016 19 Number of Products by Stage and Molecule Type, H2 2016 20 Hypothyroidism - Dormant Projects, H2 2016 27
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.